ALLO — Allogene Therapeutics Share Price
0.000.00%
Last trade - 00:00- $564.60m
- $119.97m
- $0.10m
- 22
- 14
- 55
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 1.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10,857.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.34% | ||
| Return on Equity | -55.9% | ||
| Operating Margin | -625301.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 114.09 | 0.16 | 0.1 | 0.06 | 4.12 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Directors
- Arie Belldegrun CHM (71)
- David Chang PRE (61)
- Joshua Kazam CFD (44)
- Eric Schmidt CFO (52)
- Rafael Amado EVP (57)
- Alison Moore CTO (54)
- Veer Bhavnagri CCO (38)
- David Bonderman LED (78)
- Elizabeth Barrett DRC (58)
- Vicki Sato DRC
- John DeYoung IND (58)
- Franz Humer IND (75)
- Deborah Messemer IND (63)
- Todd Sisitsky IND (49)
- Owen Witte IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 30th, 2017
- Public Since
- October 11th, 2018
- No. of Shareholders
- 68
- No. of Employees
- 232
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 209,111,516
- Address
- 210 East Grand Avenue, SOUTH SAN FRANCISCO, 94080
- Web
- https://allogene.com/
- Phone
- +1 6504572700
- Auditors
- Ernst & Young LLP
Upcoming Events for ALLO
Q4 2024 Allogene Therapeutics Inc Earnings Release
Similar to ALLO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Allogene Therapeutics share price?
As of Today at 19:10 UTC, shares in Allogene Therapeutics are trading at $2.70. This share price information is delayed by 15 minutes.
How has the Allogene Therapeutics share price performed this year?
Shares in Allogene Therapeutics last closed at $2.70 and the price had moved by -14.29% over the past 365 days. In terms of relative price strength the Allogene Therapeutics share price has underperformed the S&P500 Index by -35.79% over the past year.
What are the analyst and broker recommendations for Allogene Therapeutics?
The overall consensus recommendation for Allogene Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Allogene Therapeutics dividend yield?
Allogene Therapeutics does not currently pay a dividend.
Does Allogene Therapeutics pay a dividend?
Allogene Therapeutics does not currently pay a dividend.
When does Allogene Therapeutics next pay dividends?
Allogene Therapeutics does not currently pay a dividend.
How do I buy Allogene Therapeutics shares?
To buy shares in Allogene Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Allogene Therapeutics?
As of the previous close price of $2.70, shares in Allogene Therapeutics had a market capitalisation of $564.60m.
Where are Allogene Therapeutics shares listed?
Here are the trading details for Allogene Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALLO
What kind of share is Allogene Therapeutics?
Based on an overall assessment of its quality, value and momentum Allogene Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Allogene Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Allogene Therapeutics is $9.59. That is 255.19% above the last closing price of $2.70.
Analysts covering Allogene Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.51 for the next financial year.
Find out moreWhat is the trend in the Allogene Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allogene Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -38.32%.
As of the last closing price of $2.70, shares in Allogene Therapeutics were trading -16.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Allogene Therapeutics PE Ratio?
The Allogene Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Allogene Therapeutics?
Allogene Therapeutics' management team is headed by:
- Arie Belldegrun - CHM
- David Chang - PRE
- Joshua Kazam - CFD
- Eric Schmidt - CFO
- Rafael Amado - EVP
- Alison Moore - CTO
- Veer Bhavnagri - CCO
- David Bonderman - LED
- Elizabeth Barrett - DRC
- Vicki Sato - DRC
- John DeYoung - IND
- Franz Humer - IND
- Deborah Messemer - IND
- Todd Sisitsky - IND
- Owen Witte - IND